➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Johnson and Johnson
McKesson
Merck

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,721,620

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,721,620
Title:Swallowable drug delivery device and methods of drug delivery
Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s): Imran; Mir (Los Altos Hills, CA)
Assignee: Rani Therapeutics, LLC (San Jose, CA)
Application Number:12/978,233
Patent Claims:1. A method for delivering a therapeutic agent into the wall of a small intestine of a patient, the method comprising: swallowing a drug delivery device comprising a release element and a solid therapeutic agent shaped as a tissue penetrating member configured to be inserted into the wall of a small intestine; wherein the solid therapeutic agent would chemically degrade if released within a lumen of the gastrointestinal tract; wherein the release element releases the solid therapeutic agent from the device into the wall of the small intestine responsive to a condition in the small intestine; and wherein the solid therapeutic agent penetrates into the wall of the small intestine such that the chemical degradation of the therapeutic agent in the lumen is inhibited.

2. The method of claim 1, wherein a dose of the therapeutic agent in the capsule does not include an amount to compensate for chemical degradation and/or lack of absorption of the therapeutic agent in the gastrointestinal tract.

3. The method of claim 1, wherein the dose of therapeutic agent is reduced in an amount between about 10 to 50 percent compared to a standard oral dosage.

4. The method of 1, wherein the patient has a shortened section of small intestine and a dose of the therapeutic agent in the capsule does not include a portion to compensate for lack of absorption of the therapeutic agent in the small intestine.

5. The method of claim 1, wherein the deleterious effect comprises one of gastric cramping, diarrhea, irritable bowel or hemorrhage within the GI tract.

6. The method of claim 1, wherein the deleterious effect comprises a toxic effect on non-target tissue.

7. The method of claim 1, wherein the therapeutic agent comprises a chemotherapeutic agent for the treatment of cancer and the deleterious effect comprises at least one of a toxic effect on non-target tissue or the development of resistance to the therapeutic agent by cancerous tissue within the patient.

8. The method of claim 1, wherein the therapeutic agent comprises an antibiotic and the deleterious effect comprises the development of bacterial resistance to the antibiotic.

9. The method of claim 1, wherein the therapeutic agent comprises an antiviral agent and the deleterious effect comprises the development of a viral resistance to the antiviral agent.

10. The method of claim 1, wherein the therapeutic agent comprises an anti-seizure compound and the deleterious effect comprises a neuromuscular, cardiovascular or gastro-intestinal effect.

11. The method of claim 10, wherein the therapeutic agent comprises furosemide.

12. The method of claim 1, wherein the therapeutic agent comprises an antibody that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in the binding affinity or specificity to a target antigen site.

13. The method of claim 1, wherein the therapeutic agent comprises a polypeptide that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in binding affinity or specificity to a target binding site.

14. The method of claim 1, wherein the therapeutic agent comprises a cytokine or interferon that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in immune stimulating ability.

15. The method of claim 1, wherein the therapeutic agent comprises growth hormone that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in growth stimulating effect.

16. The method of claim 1, wherein the therapeutic agent comprises a chemotherapeutic agent for the treatment of cancer that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in cancer treatment effect.

17. The method of claim 1, wherein the therapeutic agent comprises a glucose regulating agent that is chemically degraded in the GI tract and the agent is delivered into the wall of the small intestine with minimal or no loss in glucose regulating ability.

18. The method of claim 17, wherein the glucose regulating agent comprises an insulin compound.

19. The method of claim 17, wherein the glucose regulating agent comprises an incretin compound, a GLP-1 compound or exenatide.

20. The method of claim 1, wherein the condition in the small intestine is a pH above about 7.1.

21. The method of claim 1, wherein the release element degrades in response to a chemical condition in the small intestine.

22. The method of claim 21, wherein the condition is a selected pH.

23. The method of claim 1, wherein the release element comprises an enteric material.

24. The method of claim 1, further comprising: delivering a first therapeutic agent and a second therapeutic agent, wherein the first therapeutic agent is delivered using a first tissue penetrating member and the second therapeutic agent is delivered using a second tissue penetrating member.

25. A method of drug delivery, the method comprising, swallowing a drug delivery device comprising a capsule, a drug shaped as a tissue penetrating member configured to be inserted into a wall of the small intestine an actuating mechanism, and a release element; releasing the release element in the small intestine responsive to a condition in the small intestine; and actuating the actuation mechanism to deliver the drug into the wall of the small intestine by inserting the tissue penetrating member into the wall of the small intestine.

26. The method of claim 25, wherein the drug comprises a chemotherapeutic agent, interferon, an antibody, an antibiotic, growth hormone, parathyroid hormone, a glucose regulating agent, an insulin compound, an incretin hormone, a GLP-1 compound or exenatide.

27. The method of claim 25, wherein the release element degrades in response to a chemical condition in the small intestine.

28. The method of claim 25, wherein the release element comprises an enteric material.

29. The method of claim 25, wherein the actuating mechanism comprises a spring, a cam, an electromechanical mechanism, a solenoid, or a piezoelectric material.

Details for Patent 8,721,620

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Rani Therapeutics, LLC (San Jose, CA) 2029-12-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Rani Therapeutics, LLC (San Jose, CA) 2029-12-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Rani Therapeutics, LLC (San Jose, CA) 2029-12-24 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Rani Therapeutics, LLC (San Jose, CA) 2029-12-24 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Merck
Moodys
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.